Construction of a novel vector expressing Survivin‑shRNA and fusion suicide gene yCDglyTK and its application in inhibiting proliferation and migration of colon cancer cells

Ye,Ling; Yang,Yuan; Ma,Xin‑Yu; Li,Dan; Xu,Mei‑Li; Tan,Pan; Long,Li‑Min; Wang,Hai‑Qin; Liu,Ting; Guo,Yong‑Hong

doi:10.3892/etm.2017.5154

Construction of a novel vector expressing Survivin‑shRNA and fusion suicide gene yCDglyTK and its application in inhibiting proliferation and migration of colon cancer cells

Authors:
- Ling Ye
- Yuan Yang
- Xin‑Yu Ma
- Dan Li
- Mei‑Li Xu
- Pan Tan
- Li‑Min Long
- Hai‑Qin Wang
- Ting Liu
- Yong‑Hong Guo
View Affiliations

Affiliations: Department of Geriatrics, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, P.R. China, Department of Gastroenterology, Xiangya Hospital of Central South University, Changsha, Hunan 410008, P.R. China
Published online on: September 20, 2017 https://doi.org/10.3892/etm.2017.5154
Pages: 4721-4728
Copyright: © Ye et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Despite progress achieved in cancer chemotherapy in recent decades, adverse effects remain a limiting factor for a number of patients with colorectal cancer, suggesting the requirement for novel therapeutic strategies. Gene therapy appears to be a promising strategy for treating cancer. The present study aimed to investigate the anti‑tumor effect of a combined gene therapy, using Survivin downregulation by RNAi and a fusion suicide gene yCDglyTK therapy system. A triple‑gene vector expressing Survivin‑targeted small hairpin RNA (Survivin‑shRNA) and fusion suicide gene yCDglyTK was constructed, and administered to HCT116 cells. Survivin expression decreased significantly and yCDglyTK fusion gene expression was confirmed by both reverse transcription‑quantitative polymerase chain reaction and western blot analysis. Introduction of Survivin‑shRNA into yCDglyTK/prodrug system eradicated colon cancer cells and induced apoptosis more effectively. Furthermore, this therapeutic system is able to inhibit the migration of HCT116 cells. These results indicate that the recombinant plasmid may serve as a novel gene therapy approach to treat colorectal carcinoma.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–386. 2015. View Article : Google Scholar : PubMed/NCBI
2	Marin JJ, de Medina Sanchez F, Castaño B, Bujanda L, Romero MR, Martinez-Augustin O, Moral-Avila RD and Briz O: Chemoprevention, chemotherapy and chemoresistance in colorectal cancer. Drug Metab Rev. 44:148–172. 2012. View Article : Google Scholar : PubMed/NCBI
3	Wiela-Hojeńska A, Kowalska T, Filipczyk-Cisarz E, Łapiński Ł and Nartowski K: Evaluation of the toxicity of anticancer chemotherapy in patients with colon cancer. Adv Clin Exp Med. 24:103–111. 2015. View Article : Google Scholar : PubMed/NCBI
4	Nawa A, Tanino T, Luo C, Iwaki M, Kajiyama H, Shibata K, Yamamoto E, Ino K, Nishiyama Y and Kikkawa F: Gene directed enzyme prodrug therapy for ovarian cancer: Could GDEPT become a promising treatment against ovarian cancer? Anticancer Agents Med Chem. 8:232–239. 2008. View Article : Google Scholar : PubMed/NCBI
5	Hedley D, Ogilvie L and Springer C: Carboxypeptidase-G2-based gene-directed enzyme-prodrug therapy: A new weapon in the GDEPT armoury. Nat Rev Cancer. 7:870–879. 2007. View Article : Google Scholar : PubMed/NCBI
6	Karjoo Z, Chen X and Hatefi A: Progress and problems with the use of suicide genes for targeted cancer therapy. Adv Drug Deliv Rev. 99:113–128. 2016. View Article : Google Scholar : PubMed/NCBI
7	Nouri FS, Wang X and Hatefi A: Genetically engineered theranostic mesenchymal stem cells for the evaluation of the anticancer efficacy of enzyme/prodrug systems. J Control Release. 200:179–187. 2015. View Article : Google Scholar : PubMed/NCBI
8	Zu B, Shi Y, Xu M, You G, Huang Z, Gao M and Feng W: ARE/SUZ12 dual specifically-regulated adenoviral TK/GCV system for CML blast crisis cells. J Exp Clin Cancer Res. 34:562015. View Article : Google Scholar : PubMed/NCBI
9	Rainov NG: A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther. 11:2389–2401. 2000. View Article : Google Scholar : PubMed/NCBI
10	Chai LP, Wang ZF, Liang WY, Chen L, Chen D, Wang AX and Zhang ZQ: In vitro and in vivo effect of 5-FC combined gene therapy with TNF-alpha and CD suicide gene on human laryngeal carcinoma cell line Hep-2. PLoS One. 8:e611362013. View Article : Google Scholar : PubMed/NCBI
11	Huang Q, Xia Z, You Y and Pu P: Wild Type p53 gene sensitizes rat C6 glioma cells to HSV-TK/ACV treatment in vitro and in vivo. Pathol Oncol Res. 16:509–514. 2010. View Article : Google Scholar : PubMed/NCBI
12	Park SY, Lee W, Lee J and Kim IS: Combination gene therapy using multidrug resistance (MDR1) gene shRNA and herpes simplex virus-thymidine kinase. Cancer Lett. 261:205–214. 2008. View Article : Google Scholar : PubMed/NCBI
13	Altieri DC: Survivin-The inconvenient IAP. Semin Cell Dev Biol. 39:91–96. 2015. View Article : Google Scholar : PubMed/NCBI
14	Liu JL, Gao W, Kang QM, Zhang XJ and Yang SG: Prognostic value of survivin in patients with gastric cancer: A systematic review with meta-analysis. PLoS One. 8:e719302013. View Article : Google Scholar : PubMed/NCBI
15	Xia H, Chen S, Huang H and Ma H: Survivin over-expression is correlated with a poor prognosis in esophageal cancer patients. Clin Chim Acta. 446:82–85. 2015. View Article : Google Scholar : PubMed/NCBI
16	Krieg A, Werner TA, Verde PE, Stoecklein NH and Knoefel WT: Prognostic and clinicopathological significance of survivin in colorectal cancer: A meta-analysis. PLoS One. 8:e653382013. View Article : Google Scholar : PubMed/NCBI
17	Huang J, Lyu H, Wang J and Liu B: Influence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia. Cancer Lett. 366:160–172. 2015. View Article : Google Scholar : PubMed/NCBI
18	Jaiswal PK, Goel A and Mittal RD: Survivin: A molecular biomarker in cancer. Indian J Med Res. 141:389–397. 2015. View Article : Google Scholar : PubMed/NCBI
19	Liao Y and Tang L: Inducible RNAi system and its application in novel therapeutics. Crit Rev Biotechnol. 36:630–638. 2016.PubMed/NCBI
20	Liu W, Zhu F, Jiang Y, Sun D, Yang B and Yan H: siRNA targeting survivin inhibits the growth and enhances the chemosensitivity of hepatocellular carcinoma cells. Oncol Rep. 29:1183–1188. 2013. View Article : Google Scholar : PubMed/NCBI
21	Takakura M, Kyo S, Kanaya T, Hirano H, Takeda J, Yutsudo M and Inoue M: Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res. 59:551–557. 1999.PubMed/NCBI
22	Liu T, Tang A, Zhang G, Chen Y, Zhang J, Peng S and Cai Z: Calcium phosphate nanoparticles as a novel nonviral vector for efficient transfection of DNA in cancer gene therapy. Cancer Biother Radiopharm. 20:141–149. 2005. View Article : Google Scholar : PubMed/NCBI
23	Libutti SK: New horizons for cancer gene therapy. Cancer Gene Ther. 21:12014. View Article : Google Scholar : PubMed/NCBI
24	Backman V and Roy HK: Advances in biophotonics detection of field carcinogenesis for colon cancer risk stratification. J Cancer. 4:251–261. 2013. View Article : Google Scholar : PubMed/NCBI
25	Liu T, Ye L, He Y, Chen X, Peng J, Zhang X, Yi H, Peng F and Leng A: Combination gene therapy using VEGF-shRNA and fusion suicide gene yCDglyTK inhibits gastric carcinoma growth. Exp Mol Pathol. 91:745–752. 2011. View Article : Google Scholar : PubMed/NCBI
26	Long H, Li Q, Wang Y, Li Q, Liu T and Peng J: Effective combination gene therapy using CEACAM6-shRNA and the fusion suicide gene yCDglyTK for pancreatic carcinoma in vitro. Exp Ther Med. 5:155–161. 2013. View Article : Google Scholar : PubMed/NCBI
27	Li J, Zhang G, Liu T, Gu H, Yan L and Chen B: Construction of a novel vector expressing the fusion suicide gene yCDglyTK and hTERT-shRNA and its antitumor effects. Exp Ther Med. 4:442–448. 2012. View Article : Google Scholar : PubMed/NCBI
28	Paíno T, Gangoso E, Medina JM and Tabernero A: Inhibition of ATP-sensitive potassium channels increases HSV-tk/GCV bystander effect in U373 human glioma cells by enhancing gap junctional intercellular communication. Neuropharmacology. 59:480–491. 2010. View Article : Google Scholar : PubMed/NCBI
29	Zhang G, Liu T, Chen YH, Chen Y, Xu M, Peng J, Yu S, Yuan J and Zhang X: Tissue specific cytotoxicity of colon cancer cells mediated by nanoparticle-delivered suicide gene in vitro and in vivo. Clin Cancer Res. 15:201–207. 2009. View Article : Google Scholar : PubMed/NCBI
30	Niu J, Xing C, Yan C, Liu H, Cui Y, Peng H, Chen Y, Li D, Jiang C, Li N and Yang H: Lentivirus-mediated CD/TK fusion gene transfection neural stem cell therapy for C6 glioblastoma. Tumour Biol. 34:3731–3741. 2013. View Article : Google Scholar : PubMed/NCBI
31	Stiksma J, Grootendorst DC and van der Linden PW: CA 19-9 as a marker in addition to CEA to monitor colorectal cancer. Clin Colorectal Cancer. 13:239–244. 2014. View Article : Google Scholar : PubMed/NCBI
32	Glybochko PV, Zezerov EG, Glukhov AI, Alyaev YG, Severin SE, Polyakovsky KA, Varshavsky VA, Severin ES and Vinarov AZ: Telomerase as a tumor marker in diagnosis of prostatic intraepithelial neoplasia and prostate cancer. Prostate. 74:1043–1051. 2014. View Article : Google Scholar : PubMed/NCBI
33	Crees Z, Girard J, Rios Z, Botting GM, Harrington K, Shearrow C, Wojdyla L, Stone AL, Uppada SB, Devito JT and Puri N: Oligonucleotides and G-quadruplex stabilizers: Targeting telomeres and telomerase in cancer therapy. Curr Pharm Des. 20:6422–6437. 2014. View Article : Google Scholar : PubMed/NCBI
34	Ayiomamitis GD, Notas G, Zaravinos A, Zizi-Sermpetzoglou A, Georgiadou M, Sfakianaki O and Kouroumallis E: Differences in telomerase activity between colon and rectal cancer. Can J Surg. 57:199–208. 2014. View Article : Google Scholar : PubMed/NCBI
35	Liu L, Wu W, Zhu G, Liu L, Guan G, Li X, Jin N and Chi B: Therapeutic efficacy of an hTERT promoter-driven oncolytic adenovirus that expresses apoptin in gastric carcinoma. Int J Mol Med. 30:747–754. 2012. View Article : Google Scholar : PubMed/NCBI
36	Song Y, Xin X, Zhai X, Xia Z and Shen K: Sequential combination therapy with flavopiridol and autocatalytic caspase-3 driven by amplified hTERT promoter synergistically suppresses human ovarian carcinoma growth in vitro and in mice. J Ovarian Res. 7:1212014. View Article : Google Scholar : PubMed/NCBI
37	Tian D, Sun Y, Yang Y, Lei M, Ding N and Han R: Human telomerase reverse-transcriptase promoter-controlled and herpes simplex virus thymidine kinase-armed adenoviruses for renal cell carcinoma treatment. Onco Targets Ther. 6:419–426. 2013.PubMed/NCBI
38	Cheung CH, Huang CC, Tsai FY, Lee JY, Cheng SM, Chang YC, Huang YC, Chen SH and Chang JY: Survivin-biology and potential as a therapeutic target in oncology. Onco Targets Ther. 6:1453–1462. 2013. View Article : Google Scholar : PubMed/NCBI
39	Li Y, Zhou Y, Zheng J, Niu C, Liu B, Wang M, Fang H and Hou C: Downregulation of survivin inhibits proliferation and migration of human gastric carcinoma cells. Int J Clin Exp Pathol. 8:1731–1736. 2015.PubMed/NCBI
40	Mobahat M, Narendran A and Riabowol K: Survivin as a preferential target for cancer therapy. Int J Mol Sci. 15:2494–2516. 2014. View Article : Google Scholar : PubMed/NCBI
41	Altieri DC: Targeting survivin in cancer. Cancer Lett. 332:225–228. 2013. View Article : Google Scholar : PubMed/NCBI